LABP Stock Price, Landos Biopharma, Inc. Quote, Chart

Market Summary

USD22.47+0.17

Delayed

0.76%

LABP Stock Price

View Fullscreen

LABP RSI Chart

LABP Valuation

Market Cap

70.2M

Price/Earnings (Trailing)

-2.83

Price/Sales (Trailing)

3.88

EV/EBITDA

-1.71

Price/Free Cashflow

-3.38

LABP Price/Sales (Trailing)

LABP Profitability

EBT Margin

-137.77%

Return on Equity

-107.1%

Return on Assets

-82.95%

Free Cashflow Yield

-29.62%

LABP Fundamentals

LABP Revenue

Revenue (TTM)

18.0M

LABP Earnings

Earnings (TTM)

-24.8M

Earnings Growth (Yr)

-47.45%

Earnings Growth (Qtr)

-45.4%

Breaking Down LABP Revenue

Last 7 days

0.6%

Last 30 days

3.7%

Last 90 days

301.3%

Trailing 12 Months

7648.3%

How does LABP drawdown profile look like?

LABP Financial Health

Current Ratio

4.43

LABP Investor Care

Buy Backs (1Y)

84.37%

Diluted EPS (TTM)

-4.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	0	0	0	0
2021	0	72.0M	36.0M	18.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Landos Biopharma, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 28, 2023	bassaganya-riera josep	sold	-	-	-786,299	-
Feb 28, 2023	bassaganya-riera josep	sold	-	-	-3,470,740	-
Feb 28, 2023	bassaganya-riera josep	sold	-	-	-1,463,830	-
Sep 23, 2022	rtw investments, lp	sold	-207,000	0.69	-300,000	-
Aug 05, 2022	bassaganya-riera josep	gifted	-	-	500,000	-
Aug 05, 2022	bassaganya-riera josep	gifted	-	-	-500,000	-
Mar 23, 2022	bassaganya-riera josep	gifted	-	-	-650,000	-
Dec 28, 2021	bassaganya-riera josep	gifted	-	-	-1,000,000	-
Dec 20, 2021	bassaganya-riera josep	sold	-157,804	4.754	-33,194	-
Dec 17, 2021	bassaganya-riera josep	sold	-174,096	4.836	-36,000	-

Which funds bought or sold LABP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	new	-	279	279	-%
May 15, 2024	PenderFund Capital Management Ltd.	new	-	270,842	270,842	0.07%
May 15, 2024	Black Maple Capital Management LP	new	-	223,499	223,499	0.14%
May 15, 2024	Tower Research Capital LLC (TRC)	new	-	19,246	19,246	-%
May 15, 2024	PERCEPTIVE ADVISORS LLC	unchanged	-	26,498,200	31,940,600	0.56%
May 15, 2024	Royal Bank of Canada	new	-	1,000	1,000	-%
May 14, 2024	MACQUARIE GROUP LTD	unchanged	-	262,000	316,000	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	224,856	270,986	-%
May 13, 2024	UBS Group AG	added	9,623	87,570	87,724	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	added	67.76	365,000	406,000	-%

Are Funds Buying or Selling LABP?

Are funds buying LABP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LABP

No. of Funds

Unveiling Landos Biopharma, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	perceptive advisors llc	47.7%	1,486,991	SC 13D/A
Apr 10, 2024	xontogeny, llc	9.9%	309,092	SC 13D/A
Feb 14, 2024	bassaganya-riera josep	0%	0	SC 13G/A
Mar 30, 2023	perceptive advisors llc	47.7%	14,869,915	SC 13D/A
Mar 30, 2023	xontogeny, llc	9.9%	3,090,924	SC 13D/A
Feb 14, 2023	bassaganya-riera josep	14.2%	5,720,868	SC 13G/A
Jan 13, 2023	perceptive advisors llc	36.9%	14,869,915	SC 13D/A
Nov 03, 2022	rtw investments, lp	0%	0	SC 13D/A
Oct 31, 2022	rtw investments, lp	7.83%	3,150,722	SC 13D/A
Oct 06, 2022	rtw investments, lp	9.07%	3,650,722	SC 13D/A

Recent SEC filings of Landos Biopharma, Inc.

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
Apr 25, 2024	DEFM14A	DEFM14A
Apr 16, 2024	10-K/A	Annual Report
Apr 15, 2024	PREM14A	PREM14A
Apr 10, 2024	SC 13D/A	13D - Major Acquisition
Apr 10, 2024	SC 13D/A	13D - Major Acquisition
Mar 26, 2024	DEFA14A	DEFA14A
Mar 25, 2024	DEFA14A	DEFA14A
Mar 25, 2024	DEFA14A	DEFA14A
Mar 25, 2024	8-K	Current Report

Peers (Alternatives to Landos Biopharma, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Landos Biopharma, Inc. News

Latest updates

Landos Biopharma, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2022Q4	2021Q4	2021Q3	2021Q2
Revenue	-	-	-	-	18,000,000
Operating Expenses	-68.1%	6,513,000	20,395,500	12,403,000	14,118,000
S&GA Expenses	-55.4%	3,099,000	6,951,500	3,059,000	2,596,000
R&D Expenses	-74.6%	3,414,000	13,444,000	9,344,000	11,522,000
EBITDA Margin	1.1%	-2.08	-2.10	-0.81	-0.34
Interest Expenses	-	1,281,000	-	-	-
Earnings Before Taxes	74.0%	-5,232,000	-20,097,000	-12,604,000	4,097,000
EBT Margin	-2.2%	-2.18	-2.13	-0.82	-0.35
Net Income	74.0%	-5,232,000	-20,097,000	-12,604,000	4,097,000
Net Income Margin	-2.2%	-2.18	-2.13	-0.82	-0.35
Free Cashflow	69.2%	-3,699,000	-12,020,000	-12,108,000	9,251,000

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet														(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-21.4%	29,896	38,040	43,230	46,285	51,184	45,253	49,488	58,038	77,610	92,879	105,098	118,291	110,210	30,332
Current Assets	-21.4%	29,896	38,040	43,230	46,285	51,184	45,253	49,488	58,038	77,359	92,146	104,318	117,727	109,745	29,888
Cash Equivalents	-22.5%	29,054	37,499	42,408	44,049	45,244	36,640	28,880	19,241	11,288	8,305	17,893	18,687	8,572	2,416
Net PPE	-	-	-	-	-	-	-	-	-	224	707	780	564	465	444
Liabilities	7.9%	6,742	6,249	5,566	3,015	4,160	6,122	5,475	6,510	15,507	16,611	11,180	12,679	9,031	11,310
Current Liabilities	7.9%	6,742	6,249	5,566	3,015	4,160	6,122	5,475	6,510	15,507	16,611	11,095	12,530	8,819	11,034
Shareholder's Equity	-27.2%	23,154	31,791	37,664	43,270	47,024	39,131	44,013	51,528	62,103	76,268	93,918	105,612	101,179	-
Retained Earnings	-5.7%	-164,300	-155,400	-149,200	-143,383	-139,461	-133,427	-128,200	-120,299	-109,000	-94,151	-74,054	-61,450	-65,547	-55,729
Additional Paid-In Capital	0.1%	187,382	187,122	186,877	186,629	186,094	172,575	172,016	171,816	171,182	170,241	167,440	166,805	166,429	1,633
Shares Outstanding	0.1%	3,119	3,117	3,117	3,117	3,117	4,025	4,025	4,025	4,025	4,025	3,666	2,988	-	-
Float	-	-	-	-	5,600	-	-	-	8,500	-	-	-	89,900	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	-71.0%	-8,498	-4,969	-2,228	-5,110	-8,170	-3,699	-7,573	-17,997	-16,502	-12,057	-11,844	9,400	-12,560	-8,391	-5,379	-5,824	-3,368
Share Based Compensation	6.1%	260	245	248	254	224	196	200	634	941	2,428	355	312	1,023	833	-	-	-
Cashflow From Investing	-100.0%	-	63.00	634	3,974	3,104	11,471	17,212	25,871	19,506	1,796	10,831	715	-72,048	6,930	3,464	2,030	1,707
Cashflow From Financing	-	-	-	-	-99.00	13,666	-	-	-	-	624	219	-	90,764	-	-	-	-
Buy Backs	-	-	-	-	-	3,000	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LABP Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 3,151	$ 3,326
General and administrative	6,144	3,153
Total operating expenses	9,295	6,479
Loss from operations	(9,295)	(6,479)
Other income:
Loss from foreign exchange	(3)	(4)
Interest and other income, net	401	449
Other income, net	398	445
Net loss	$ (8,897)	$ (6,034)
Net loss per common stock, basic	$ (1.43)	$ (0.93)
Net loss per common stock, diluted	$ (1.43)	$ (0.93)
Weighted-average shares used to compute net loss income per share, basic	6,207,637	6,484,233
Weighted-average shares used to compute net loss income per share, diluted	6,207,637	6,484,233
Net loss	$ (8,897)	$ (6,034)
Unrealized gain on available-for-sale marketable securities	0	136
Comprehensive loss	$ (8,897)	$ (5,898)

LABP Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 29,004	$ 37,499
Restricted Cash	50	50
Prepaid expenses and other current assets	842	491
Total current assets	29,896	38,040
Total assets	29,896	38,040
Current liabilities:
Accounts payable	1,565	1,375
Accrued liabilities	5,177	4,874
Total current liabilities	6,742	6,249
Total liabilities	6,742	6,249
Commitments and contingencies (Note 7)
Stockholders' equity:
Preferred stock, $0.01 par value; 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.01 par value; 20,000,000 shares authorized, 3,116,729 shares issued and outstanding as of March 31, 2024 and December 31, 2023	31	31
Additional paid-in capital	187,382	187,122
Accumulated deficit	(164,259)	(155,362)
Total stockholders' equity	23,154	31,791
Total liabilities and stockholders' equity	$ 29,896	$ 38,040

About Landos Biopharma, Inc.

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; and LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.

CEO	Mr. Gregory Oakes
WEBSITE	https://landosbiopharma.com
INDUSTRY	Biotechnology
EMPLOYEES	22

Landos Biopharma, Inc. Frequently Asked Questions

What is the ticker symbol for Landos Biopharma, Inc.? What does LABP stand for in stocks?

LABP is the stock ticker symbol of Landos Biopharma, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Landos Biopharma, Inc. (LABP)?

As of Fri May 17 2024, market cap of Landos Biopharma, Inc. is 70.24 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LABP stock?

You can check LABP's fair value in chart for subscribers.

What is the fair value of LABP stock?

You can check LABP's fair value in chart for subscribers. The fair value of Landos Biopharma, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Landos Biopharma, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LABP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Landos Biopharma, Inc. a good stock to buy?

The fair value guage provides a quick view whether LABP is over valued or under valued. Whether Landos Biopharma, Inc. is cheap or expensive depends on the assumptions which impact Landos Biopharma, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LABP.

What is Landos Biopharma, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, LABP's PE ratio (Price to Earnings) is -2.83 and Price to Sales (PS) ratio is 3.88. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LABP PE ratio will change depending on the future growth rate expectations of investors.